Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
Public ClinicalTrials.gov record NCT02706899. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Study identification
- NCT ID
- NCT02706899
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Seagen Inc.
- Industry
- Enrollment
- 19 participants
Conditions and interventions
Conditions
Interventions
- Azacitidine Drug
- Placebo (for 33A) Drug
- vadastuximab talirine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2016
- Primary completion
- Nov 5, 2017
- Completion
- Nov 5, 2017
- Last update posted
- Feb 11, 2019
2016 – 2017
United States locations
- U.S. sites
- 34
- U.S. states
- 22
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | — | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Rocky Mountain Cancer Centers, LLP | Aurora | Colorado | — | — |
| Colorado Blood Cancer Institute | Denver | Colorado | — | — |
| University of Colorado Hospital | Denver | Colorado | — | — |
| Cancer Specialisits of North Florida | Fleming Island | Florida | — | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Georgia Regents University Hospital | Augusta | Georgia | — | — |
| Rush University Medical Center | Chicago | Illinois | — | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | — | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | — | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | — | — |
| University of Minnesota Medical Center (UMMC) | Minneapolis | Minnesota | — | — |
| Bozeman Deaconess Health Group | Bozeman | Montana | — | — |
| Hackensack University Medical Center | Hackensack | New Jersey | — | — |
| The University of New Mexico Cancer Research and Treatment Center | Albuquerque | New Mexico | — | — |
| Weill Cornell | Brooklyn | New York | — | — |
| Westchester Medical Center | Hawthorne | New York | 10532 | — |
| Columbia University Medical Center | New York | New York | — | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| Case Western Reserve University (CWRU) - University Hospitals Case Medical Center | Cleveland | Ohio | — | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Providence Portland Research Center | Portland | Oregon | 97213 | — |
| Oregon Health & Science | Portland | Oregon | 97239 | — |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia | Pennsylvania | — | — |
| Medical University of South Carolina | Charleston | South Carolina | — | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | — | — |
| Texas Oncology - Austin Midtown | Austin | Texas | — | — |
| Baylor University Medical Center | Dallas | Texas | — | — |
| MD Anderson Cancer Center | Houston | Texas | — | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | — | — |
| Swedish Medical Center | Seattle | Washington | — | — |
| Froedtert & Medical College of Wisconson Clinical Cancer Center | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02706899, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2019 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02706899 live on ClinicalTrials.gov.